Medroxyprogesterone Acetate

MARLTON, N.J., March 12, 2025 /PRNewswire/ -- A growing number of women who received Depo-Provera injections are coming forward with serious health concerns following new research linking the contraceptive drug to an increased risk of meningioma, a type of intracranial tumor. Many individuals who used progestogen-only injections such as Depo-Provera (DMPA, medroxyprogesterone acetate) for extended periods have reported symptoms such as chronic headaches, vision problems, dizziness, memory impairment, and seizures—common neurological symptoms associated with brain masses. If you or a loved one developed a meningioma after long-term use of Depo-Provera, legal options may be available. However, due to strict statutes of limitations, those affected have only a limited window of time to take action. In some states, the statute of limitations for product liability cases is just one year from the date of injury or discovery. Console & Associates P.C. is reviewing cases for women who have been diagnosed with progesterone-induced meningiomas after prolonged use of this birth control injection. What Is the Connection Between Depo-Provera and Meningiomas? Depo-Provera is a progestin-based contraceptive shot used by millions worldwide for birth control, as well as for treating endometriosis, menstrual irregularities, and other hormonal conditions. However, a March 2024 study published in the British Medical Journal uncovered a troubling link. Researchers from France's National Agency for Medicines and Health Products Safety determined that prolonged use of medroxyprogesterone acetate (DMPA) increases the risk of developing meningiomas by five and a half times. Meningiomas are intracranial tumors that form in the membranes surrounding the brain and spinal cord. While typically noncancerous, they can still cause severe neurological symptoms, including headaches, blurred vision, difficulty speaking, and cognitive impairment. Larger tumors may require surgery, radiation, or lifelong medical monitoring, posing significant health and financial burdens. How Many Women Could Be at Risk? Depo-Provera has been widely prescribed since its FDA approval in 1992, with millions of women worldwide using the contraceptive shot for birth control. In the United States alone, nearly 1.5 million women rely on Depo-Provera annually, according to the Guttmacher Institute. Given the newly identified risks of meningioma, a substantial number of women may have unknowingly developed progesterone-induced meningiomas after prolonged use. Did Pfizer Fail to Warn About the Risks? Despite growing concerns about the link between Depo-Provera and intracranial tumors, Pfizer—the drug's manufacturer—did not include this risk on its warning labels for decades. The company only recently acknowledged the potential danger, confirming plans to update patient information leaflets and product labels. For years, women trusted Depo-Provera as a safe and effective birth control injection, unaware of the long-term health risks. Without clear warnings, many individuals lacked the information needed to make informed healthcare decisions. Now, countless women are left with neurological symptoms, permanent disabilities, and costly medical treatments—all of which could have been avoided had the manufacturer acted sooner. Women who used Depo-Provera (DMPA, medroxyprogesterone acetate) for more than a year and were later diagnosed with meningiomas may have grounds for legal action. Lawsuits could seek compensation for medical expenses, lost wages, long-term care costs, and emotional distress. What Are Your Legal Options If You Were Diagnosed with a Brain Tumor? Those diagnosed with meningiomas after using Depo-Provera may qualify for a mass tort lawsuit, a type of legal action allowing multiple plaintiffs to hold the manufacturer accountable. Due to strict statutes of limitations, women affected by Depo-Provera birth control injection side effects must act quickly to protect their legal rights. Console & Associates P.C. is currently evaluating claims for women who meet the following criteria: Used Depo-Provera (DMPA, medroxyprogesterone acetate) for one year or longer; Received a meningioma diagnosis; and Experienced headaches, blurred vision, seizures, memory loss, or other neurological symptoms Many individuals facing a meningioma diagnosis require extensive medical treatments, including surgery, radiation therapy, or lifelong neurological monitoring. A successful lawsuit can provide the financial support necessary to cover these expenses, ensuring that those affected receive the care they need. However, holding Pfizer accountable is not just about compensation—it is about ensuring that pharmaceutical companies prioritize patient safety over profits. The mass tort lawyers at Console & Associates, P.C. are dedicated to advocating on behalf of those injured by dangerous and defective drugs. Anyone interested in learning more about Depo-Provera Lawsuits should contact the firm for a no-obligation consultation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Console & Associates, P.C. 866-778-5500 [email protected] SOURCE Console & Associates, P.C. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

BOSTON--( BUSINESS WIRE )-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics , (“Seaport”) a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the publication of new data showcasing the Glyph TM platform’s unique ability to enhance drug transport through the lymphatic system for increased therapeutic exposure. The paper, published in Molecular Pharmaceutics , is the first to show the impact of changing the drug attachment point of a lymph-directed prodrug on lymphatic drug transport and targeted drug exposure. It also deepens the evidence supporting Glyph’s ability to render a wide variety of molecules, including immunomodulators, more amenable to lymphatic transport and thus providing them with direct access to the immune system. The full text of the announcement from Seaport is as follows: Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with Glyph TM Platform Published data shows new site of Glyph prodrug attachment demonstrated highest reported level of lymphatic transport to date of the studied immunomodulatory drug New linkers display up to two-fold higher release in lymph nodes compared to top-performing previously reported linkers Research builds on prior evidence supporting the versatility of Glyph platform BOSTON, February 12, 2025 – Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the publication of new data showcasing the Glyph TM platform’s unique ability to enhance drug transport through the lymphatic system for increased therapeutic exposure. The paper, published in Molecular Pharmaceutics , is the first to show the impact of changing the drug attachment point of a lymph-directed prodrug on lymphatic drug transport and targeted drug exposure. It also deepens the evidence supporting Glyph’s ability to render a wide variety of molecules, including immunomodulators, more amenable to lymphatic transport and thus providing them with direct access to the immune system. The study evaluated ways of modifying mycophenolic acid (MPA), an immunomodulatory drug, to improve its absorption through the lymphatic system, and increase its concentration in lymph nodes, shown in preclinical models. Specifically, a comparison between distinct attachment points on the same drug molecule was made. A newly examined phenol attachment point showed the highest lymphatic transport of MPA reported to date – approximately 55 percent – and up to two-fold higher release in lymph nodes compared to the previously reported acid attachment point. The research demonstrated the impact of linker characteristics on the extent of lymphatic transport and release in the lymph nodes. Overall, these results help to underscore the benefits of a tailored lymphatic-targeting prodrug design approach. “ This research expands our understanding of lymphatic delivery and offers new insights for more effectively designing drugs with higher exposures at their intended targets, including immunomodulatory drugs used to treat a wide range of diseases,” said Christopher Porter, Ph.D., an original Co-inventor of the Glyph technology and Director of the Monash Institute of Pharmaceutical Sciences at Monash University in Melbourne. “ This study highlights the importance of integrating a careful and individualized balance of intestinal stability, transport efficiency and release in the mesenteric lymph nodes to maximize therapeutic exposures as part of a tailored prodrug design approach.” With the Glyph platform, drugs are absorbed like dietary fats through the intestinal lymphatic system and transported into circulation. The Glyph platform has the potential to be widely applied to many therapeutic molecules that have high first-pass metabolism leading to low bioavailability and/or side effects, including liver enzyme elevations or hepatotoxicity. Seaport exclusively licensed this technology from Monash University based on the pioneering research of the Porter Research Group, including co-inventors Professor Porter and Jamie Simpson, Ph.D., who is now Head of Chemistry at Seaport Therapeutics. “ Our Glyph platform allows for a bespoke design approach, and this research reinforces the significance of the innovation behind our prodrug chemistry technology,” said Daniel Bonner, Ph.D., Co-founder, Senior Vice President, Platform, at Seaport Therapeutics. “ Most importantly, Glyph has been clinically validated with demonstrated proof-of-concept data in humans and is being applied across Seaport’s pipeline of novel neuropsychiatric medicines, with enormous potential across a broad range of applications beyond CNS and neuropsychiatry.” About the Glyph TM Platform Glyph TM is Seaport’s proprietary technology platform which uses the lymphatic system to enable and enhance the oral administration of drugs. With the Glyph platform, drugs are absorbed like dietary fats through the intestinal lymphatic system and transported into circulation. The Glyph platform has the potential to be widely applied to many therapeutic molecules that have high first-pass metabolism leading to low bioavailability and/or side effects, including liver enzyme elevations or hepatotoxicity. Seaport exclusively licensed this technology from Monash University based on the pioneering research of the Porter Research Group. Advanced initially at PureTech Health and now at Seaport, Glyph has been applied to create therapeutic candidates for the Company’s pipeline resulting in new intellectual property, including composition of matter. The group and its collaborators have published research in Nature Metabolism , Frontiers in Pharmacology , Journal of Controlled Release and Molecular Pharmaceutics supporting the Glyph platform’s capabilities. See Glyph in action here . About Seaport Therapeutics Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph TM technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit www.seaporttx.com . About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh. Cautionary Note Regarding Forward-Looking Statements This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to Seaport’s development plans for its pipeline of neuropsychiatric therapeutics based on the Glyph Platform, the applicability of the platform beyond neuropsychiatry, potential benefits to patients, and Seaport’s and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.